Skip to content
10-Q

Quarterly Report

Immuneering Corporation IMRX

0001790340-26-000057

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 64.66M sh
Shares Diluted Q1 2026 · Mar 31, 2025 35.53M sh
Capex Q1 2026 · Mar 31, 2026 $79.93K
Capex Q1 2026 · Mar 31, 2025 $8.95K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$18.43M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$14.08M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $47.32M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $128.65M
Stockholders Equity Q1 2026 · Mar 31, 2026 $206.52M
Stockholders Equity Q1 2026 · Dec 31, 2025 $218.48M
Stockholders Equity Q1 2026 · Mar 31, 2025 $41.84M
Stockholders Equity Q1 2026 · Dec 31, 2024 $41.39M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.97M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.07M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.29M
Total Liabilities Q1 2026 · Dec 31, 2025 $13.5M
Current Assets Q1 2026 · Mar 31, 2026 $161.41M
Current Assets Q1 2026 · Dec 31, 2025 $176.25M
Total Assets Q1 2026 · Mar 31, 2026 $214.81M
Total Assets Q1 2026 · Dec 31, 2025 $231.99M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.21
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.42
Eps Basic Q1 2026 · Mar 31, 2026 −$0.21
Eps Basic Q1 2026 · Mar 31, 2025 −$0.42
Sga Expense Q1 2026 · Mar 31, 2026 $4.68M
Sga Expense Q1 2026 · Mar 31, 2025 $4.01M
Rd Expense Q1 2026 · Mar 31, 2026 $10.65M
Rd Expense Q1 2026 · Mar 31, 2025 $11.47M
Net Income Q1 2026 · Mar 31, 2026 −$13.46M
Net Income Q1 2026 · Mar 31, 2025 −$15.05M
Operating Income Q1 2026 · Mar 31, 2026 −$15.34M
Operating Income Q1 2026 · Mar 31, 2025 −$15.48M